Kedudukan dalam Saham
#10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Harga Saham
$14.66
Disegerakkan terakhir: 2026-08-28
Perubahan (1 hari)
-2.67%
Perubahan (1 tahun)
557.32%
Perdagangan Climb Bio, Inc. (CLYM)
Harga CLYM dengan permodalan pasaran b
Modal pasaran bagi Climb Bio, Inc.(CLYM)
Modal Pasaran: $839.37M
Sehingga August 2026, Climb Bio, Inc. mempunyai modal pasaran sebanyak $839.37M. Ini menjadikan Climb Bio, Inc. syarikat ke-10440th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Climb Bio, Inc. dari 2024 hingga 2026
CLYM berbanding dengan 5 teratas yang paling popular stocks
| Harga CLYM |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.264T
|
+627,019.37%
|
|
|
|
|
$4.701T
|
+559,994.09%
|
|
|
|
|
$4.177T
|
+497,554.81%
|
|
|
|
|
$3.817T
|
+454,692.24%
|
|
|
|
|
$2.866T
|
+341,385.66%
|
